Official Title
Study of Acquired Immunity in Patients With Lung Cancer and COVID-19 Infection
Brief Summary

Observational, retrospective data collection and prospective IgG analysis, and multicenter study. The main objective of the study is th description of the characteristics and evolution of patients with lung cancer who have acquired COVID-19 infection. For the identification of patients who contract COVID-19 infection, the IgG+ blood test by ELISA method will be used.

Detailed Description

Non-post-authorization study, retrospective of data collection and prospective of IgG
analysis, observational and multicenter.

The study will be extended to all the sites of the Spanish Lung Cancer Group, more than 170
centers and 500 professionals, and it is expected that around 1,500 IgG tests will be carried
out.

The study has three phases:

The scope of phase I is the identification of acquired immunity (IgG) in patients with lung
cancer, whether or not they have presented symptoms of having suffered from COVID19. In
addition, the description of the characteristics and evolution of patients with lung cancer
who have contracted COVID-19 infection will be carried out.

For the identification of patients who contract COVID-19 infection, the IgG+ test in blood
will be used by ELISA method.

The scope of phase II is the confirmation of the presence of antibodies (IgG) in patients who
tested positive in Phase I of the study a few weeks after the first diagnosis made through
the SOLID study.

The scope of phase III is the confirmation of the presence of antibodies (IgG) in patients
with lung cancer who have been vaccinated with any of the available and authorized vaccines
for SARS-COV2 and 6 months after said administration.

Completed
Lung Cancer
COVID
Corona Virus Infection

Diagnostic Test: IgG test

IgG+ blood test by ELISA method.

Eligibility Criteria

Inclusion Criteria:

1. Patients diagnosed with lung cancer at any stage of the disease

2. Age ≥ 18

3. Patients who have signed the informed consent for this study

Exclusion Criteria:

1. Patients who have not signed or do not wish to sign the informed consent for this study

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Spain
Locations

Hospital General Universitario de Elche
Elche, Alicante, Spain

ICO Hospitalet
Hospitalet de Llobregat, Barcelona, Spain

Hospital Universitario Insular de Gran canaria
Las Palmas De Gran Canaria, Gran Canaria, Spain

Hospital Universitario de Torrejón
Torrejón, Madrid, Spain

Hospital Universitario Son Llàtzer
Palma De Mallorca, Mallorca, Spain

Complexo Hospitalario Universitario de Vigo
Vigo, Pontevedra, Spain

Complejo Hospitalario de A Coruña
A Coruña, Spain

Hospital La Esperanza
A Coruña, Spain

Hospital Universitario de Ferrol
A Coruña, Spain

Hospital Virgen de los Lirios
Alicante, Spain

Hospital Germans Trias i Pujol
Badalona, Spain

Hospital Clínic de Barcelona
Barcelona, Spain

Hospital de la Santa Creu i Sant Pau
Barcelona, Spain

Hospital Universitari Dexeus
Barcelona, Spain

Hospital Universitario Cruces
Bilbao, Spain

Hospital Universitario de Burgos
Burgos, Spain

Hospital Universitario Puerto Real
Cadiz, Spain

Hospital General La Mancha Centro
Ciudad Real, Spain

Hospital Universitario San Pedro de Alcántara
Cáceres, Spain

Hospital Universitario Puerta del Mar
Cádiz, Spain

Hospital Universitario Reina Sofía
Córdoba, Spain

Hospital Universitario de Vinalopó
Elche, Spain

Hospital Dr. Josep Trueta
Girona, Spain

Hospital Universitario de Guadalajara
Guadalajara, Spain

Complejo Hospitalario de Jaén
Jaén, Spain

Complejo Asistencial Universitario de León
León, Spain

Hospital universitari Arnau de Vilanova
Lleida, Spain

Hospital San Pedro
Logroño, Spain

Hospital Universitario Lucus Augusti
Lugo, Spain

Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain

Hospital Universitario 12 de Octubre
Madrid, Spain

Hospital Universitario La Paz
Madrid, Spain

Hospital Puerta de Hierro
Madrid, Spain

Clínica Universidad de Navarra
Madrid, Spain

Hospital de Sanchinarro
Madrid, Spain

Hospital General Universitario Gregorio Marañón
Madrid, Spain

Hospital Severo Ochoa
Madrid, Spain

Hospital Universitario de Móstoles
Madrid, Spain

Hospital Universitario del Henares
Madrid, Spain

Hospital Universitario Fundación Alcorcón
Madrid, Spain

Hospital Universitario Infanta Cristina
Madrid, Spain

Hospital Universitario Infanta Leonor
Madrid, Spain

Hospital Universitario Infanta Sofía
Madrid, Spain

Hospital Universitario Príncipe de Asturias
Madrid, Spain

Hospital General Universitario de Málaga
Málaga, Spain

Hospital Costa del Sol
Málaga, Spain

Complejo Hospitalario Universitario de Ourense Santa María Nai
Ourense, Spain

Hospital Universitario Son Espases
Palma De Mallorca, Spain

Clínica Universidad de Navarra
Pamplona, Spain

Complejo Hospitalario de Navarra
Pamplona, Spain

Hospital Universitario Sant Joan de Reus
Reus, Spain

Hospital Universitario de Salamanca
Salamanca, Spain

Hospital Universitario de Canarias
Santa Cruz De Tenerife, Spain

Hospital General de Segovia
Segovia, Spain

Hospital Virgen del Rocío
Sevilla, Spain

Hospital Sant Pau i Santa Tecla
Tarragona, Spain

Hospital Universitario Nuestra Señora de Candelaria
Tenerife, Spain

Hospital Universitari i Politécnic La Fe
Valencia, Spain

Hospital Clínico Universitario de Valencia
Valencia, Spain

Hospital General de Valencia
Valencia, Spain

Hospital Arnau de Vilanova
Valencia, Spain

Hospital de Manises
Valencia, Spain

Hospital General Universitario de Valencia
Valencia, Spain

Hospital Lluís Alcanyís
Valencia, Spain

Hospital Universitario Dr. Peset
Valencia, Spain

Hospital Clínico Universitario de Valladolid
Valladolid, Spain

Hospital Universitario Río Ortega
Valladolid, Spain

Complejo Hospitalario Zamora
Zamora, Spain

Mariano Provencio, MD, Principal Investigator
Hospital Puerta de Hierro de Majadahonda de Madrid

Fundación GECP
NCT Number
Keywords
IgG
Coronavirus
Covid-19
lung cancer
MeSH Terms
Infections
Communicable Diseases
COVID-19
Coronavirus Infections
Lung Neoplasms